Hartford Investment Management Co. Sells 1,294 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Hartford Investment Management Co. reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 77,027 shares of the biopharmaceutical company’s stock after selling 1,294 shares during the quarter. Hartford Investment Management Co.’s holdings in Gilead Sciences were worth $7,115,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of GILD. Certuity LLC lifted its stake in shares of Gilead Sciences by 44.2% in the fourth quarter. Certuity LLC now owns 8,395 shares of the biopharmaceutical company’s stock worth $775,000 after acquiring an additional 2,574 shares during the period. Leavell Investment Management Inc. lifted its stake in shares of Gilead Sciences by 8.8% in the fourth quarter. Leavell Investment Management Inc. now owns 4,870 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 395 shares in the last quarter. Quent Capital LLC boosted its stake in Gilead Sciences by 42.5% during the 4th quarter. Quent Capital LLC now owns 2,717 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 811 shares during the last quarter. Sovran Advisors LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $506,000. Finally, Stonebridge Financial Group LLC purchased a new position in Gilead Sciences during the 4th quarter worth $55,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.7 %

Shares of NASDAQ:GILD opened at $96.14 on Wednesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The company has a market cap of $119.82 billion, a PE ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18. The stock’s 50-day moving average is $93.07 and its 200 day moving average is $86.99.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 in the last three months. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. Robert W. Baird lifted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Truist Financial increased their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Oppenheimer lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.